New biologic for the treatment of NHL packs one-two punch
August 4th 2003Clinicians can now offer their patients with non-Hodgkin?s lymphoma (NHL) therapy that combines targeted radiation with patient-specific dosing. The FDA recently approved tositumomab and iodine I-131 tositumomab (Bexxar, Corixa Corporation/GlaxoSmithKline) for the treatment of patients with CD20-positive, follicular NHL, with and without transformation, whose disease is refractory to rituxamab (Rituxan, Genentech) and has relapsed following chemotherapy. Training can be requested and orders placed by calling (877) 423-9927. Corixa recently began supplying Bexxar to cancer treatment centers.
Bar-code technology making progress, study finds
August 4th 2003Pharmaceutical manufacturers, distributors, and pharmacies are gearing up to make fuller use of bar codes to prevent errors along the medication supply chain, according to the first industry-wide survey by the Healthcare Distribution Management Association.